Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus (STRIDE)

May 20, 2026 updated by: CereVasc Inc

Pivotal Study to Evaluate the Safety and Effectiveness of the CereVasc® eShunt® System in the Treatment of Normal Pressure Hydrocephalus

Prospective, multi-center, randomized, controlled trial of the eShunt System in the treatment of patients with normal pressure hydrocephalus.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The STRIDE study is a prospective, multi-center, randomized, controlled trial of the eShunt System in the treatment of patients with normal pressure hydrocephalus.

Study Type

Interventional

Enrollment (Estimated)

230

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Argentina
      • Buenos Aires, Argentina, C1426B
        • Recruiting
        • Clínica La Sagrada Familia
        • Contact:
        • Principal Investigator:
          • Pedro Lylyk, MD
  • Canada
    • Alberta
      • Calgary, Alberta, Canada, T2N 4N1
        • Recruiting
        • University of Calgary - Foothills Medical Centre
        • Contact:
        • Principal Investigator:
          • Mark G Hamilton, MDCM, FRCSC, FAANS, FCNS
    • Ontario
      • Toronto, Ontario, Canada, M5C 2W6
        • Recruiting
        • St. Michael's Hospital
        • Contact:
        • Principal Investigator:
          • Vitor Mendes Pereira, MD
  • United States
    • California
      • Los Angeles, California, United States, 90033
        • Active, not recruiting
        • University of Southern California
    • Connecticut
      • New Haven, Connecticut, United States, 06511
    • Florida
      • Jacksonville, Florida, United States, 32207
        • Recruiting
        • Baptist Medical Center - Jacksonville
        • Principal Investigator:
          • Ricardo Hanel, MD, PhD
        • Contact:
      • Tampa, Florida, United States, 33606
        • Active, not recruiting
        • University of South Florida
    • Illinois
      • Chicago, Illinois, United States, 60611
      • Park Ridge, Illinois, United States, 60068
        • Recruiting
        • Advocate Lutheran General Hospital
        • Principal Investigator:
          • Demetrius Lopes, MD
        • Contact:
    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Active, not recruiting
        • Indiana University
    • Kansas
      • Kansas City, Kansas, United States, 66160
        • Recruiting
        • University of Kansas Medical Center
        • Principal Investigator:
          • Koji Ebersole, MD
        • Contact:
    • Kentucky
      • Lexington, Kentucky, United States, 40506
        • Active, not recruiting
        • University of Kentucky Research Foundation
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Active, not recruiting
        • Massachusetts General Hospital
      • Boston, Massachusetts, United States, 02115
        • Active, not recruiting
        • Brigham and Women's Hospital
      • Boston, Massachusetts, United States, 02215
        • Active, not recruiting
        • Beth Israel Deaconess Medical Center
    • Michigan
      • West Bloomfield, Michigan, United States, 48322
        • Recruiting
        • Henry Ford Health
        • Contact:
        • Principal Investigator:
          • Pouya Entezami, MD
    • New Jersey
      • Camden, New Jersey, United States, 08103
        • Active, not recruiting
        • Cooper Neurological Institute
    • New York
      • Albany, New York, United States, 12208
        • Recruiting
        • Albany Medical Center
        • Principal Investigator:
          • Alexandra Paul, MD
        • Contact:
      • Buffalo, New York, United States, 14203
        • Active, not recruiting
        • University at Buffalo Neurosurgery
      • Manhasset, New York, United States, 11030
        • Recruiting
        • Northwell Health
        • Contact:
        • Principal Investigator:
          • Mark B. Eisenberg, MD
      • New York, New York, United States, 10065
        • Recruiting
        • Weill Cornell Medicine
        • Contact:
        • Principal Investigator:
          • Srikanth Boddu, MD
      • New York, New York, United States, 10016
      • New York, New York, United States, 10075
        • Recruiting
        • Lenox Hill Hospital
        • Principal Investigator:
          • Yafell Serulle, MD, PhD
        • Contact:
      • New York, New York, United States, 10029
        • Active, not recruiting
        • Icahn School of Medicine at Mount Sinai
      • Rochester, New York, United States, 14642
      • The Bronx, New York, United States, 10467
        • Active, not recruiting
        • Montefiore Medical Center
    • Ohio
      • Cleveland, Ohio, United States, 44195
        • Recruiting
        • Cleveland Clinic
        • Contact:
        • Principal Investigator:
          • Mark Bain, MD
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19107
        • Recruiting
        • Thomas Jefferson University
        • Contact:
        • Principal Investigator:
          • Pascal M Jabbour, MD
    • Rhode Island
      • Providence, Rhode Island, United States, 02903
        • Active, not recruiting
        • Rhode Island Hospital
    • Texas
      • Dallas, Texas, United States, 75390
        • Recruiting
        • University of Texas Southwestern Medical Center
        • Principal Investigator:
          • Babu Welch, MD
        • Contact:
    • Virginia
      • Richmond, Virginia, United States, 23298
        • Recruiting
        • Virginia Commonwealth University
        • Contact:
        • Principal Investigator:
          • John Reavey-Cantwell, MD
        • Contact:
          • Mally Jones
          • Phone Number: mallory.jones@vcuhealth.org

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

Each subject must meet the following criteria:

  1. Patients ≥60 years old on the day of study informed consent
  2. Patient or legally authorized representative is able and willing to provide written informed consent
  3. History or evidence of gait impairment with a duration ≥3 months

  4. Clinical presentation consistent with NPH including two or more of the clinical triad (i.e., history of gait disturbance, progressive mental deterioration, and urinary urgency or incontinence), together with all of the following:

    1. Brain MRI signs of ventricular enlargement disproportionate to cerebral atrophy (Evans' Index >0.3) and the absence of severe hippocampal atrophy,
    2. Pre-procedure spinal tap test or lumbar drain with subsequent gait disturbance improvement (Timed Up and Go Test) of at least 20%,
    3. CSF opening pressure ≥8 cmH2O,
    4. Baseline cognitive evaluation assessed by Montreal Cognitive Assessment (MoCA) test score ≥12
  5. Patient is willing and able to attend all scheduled visits and comply with study procedures.
  6. Confirmation of anatomy suitable for the eShunt procedure, as determined by evaluation of pre-procedure imaging (CT and MRI) and approved by an independent anatomical screening committee.

Exclusion Criteria:

Each subject may not:

  1. Be unable to walk 10 meters (33 feet) with or without an assistive device
  2. Be diagnosed with obstructive hydrocephalus
  3. Have an active systemic infection or infection detected in CSF
  4. Have had prior or existing shunts, endoscopic third ventriculostomy, or any previous surgical intervention for hydrocephalus
  5. Demonstrate hypersensitivity or contraindication to heparin or radiographic contrast agents against which the subject cannot be adequately pre-medicated, desensitized or where no alternative is available
  6. Have occlusion or stenosis of the internal jugular vein which would prohibit access to the IPS
  7. Present with venous distension in the neck on physical exam
  8. Have medical conditions associated with prolonged elevation of jugular venous pressure, including jugular vein stenosis or stricture, right sided heart failure, cirrhosis of the liver, arteriovenous fistulas in the arm for dialysis purposes, or an arterial venous fistula or malformation in the neck or brain
  9. Have history of bleeding diatheses, coagulopathy or refuse to consent for blood transfusion in cases of emergency
  10. Have had an ischemic stroke or transient ischemic attack within 180 days of eShunt procedure
  11. Have documented evidence of a deep vein thrombosis superior to the popliteal vein
  12. Have intrinsic blood clotting disorder
  13. Have medical conditions requiring anticoagulation which is unable to be managed to allow for surgical procedure
  14. Have presence of a posterior fossa tumor or mass
  15. Have a life expectancy <1 year
  16. Be currently participating in another interventional (drug, device, etc.) research project that may confound the results of this study.
  17. Have established diagnosis of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, or Lewy body dementia
  18. Be diagnosed with schizophrenia or any psychiatric diagnosis (including depression) that may complicate outcome evaluation
  19. Need an intracranial neurosurgical procedure within 180 days of study index procedure
  20. Be unwilling or unable to comply with follow-up requirements
  21. Have mRS of 0, 5, or 6

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: eShunt System
Endovascular placement of the eShunt Implant
Device: CereVasc eShunt System

The eShunt System consists of the following components:

  • eShunt Implant
  • eShunt Delivery Catheter and Transfer Tool
  • eShunt Anchor
Other Names:
  • eShunt System
  • eShunt Implant
Active Comparator: VP Shunt
Surgical ventriculo-peritoneal shunt procedure
Device: VP Shunt
Control arm - VP shunt

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Primary Effectiveness Endpoint
Time Frame: 6 months
The Primary Effectiveness Endpoint of this study is change in gait impairment at 6-months, compared to baseline. Change in gait impairment is defined as reduction in time required to complete the Timed Up and Go (TUG) test (stand up, walk 3m, turnaround, walk 3m, sit down).
6 months
Primary Safety Endpoint
Time Frame: 6 months
All adverse events will be reported for the investigational (eShunt System) and control (VP shunt) arms. Safety will be analyzed based on a review of all AEs in the investigational arm compared to the control arm, through 6-months post-procedure to demonstrate an acceptable safety profile of the eShunt System.
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

CereVasc Inc

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 26, 2024

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

June 1, 2031

Study Registration Dates

First Submitted

July 5, 2024

First Submitted That Met QC Criteria

July 5, 2024

First Posted (Actual)

July 12, 2024

Study Record Updates

Last Update Posted (Actual)

May 22, 2026

Last Update Submitted That Met QC Criteria

May 20, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CLIN 0036

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Normal Pressure Hydrocephalus

Clinical Trials on CereVasc eShunt System

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe